German rider Patrik Sinkewitz (Farnese Vini – Neri Sottoli) is facing a lifetime ban after testing positive for human growth hormones from a blood sample taken during the GP di Lugano in late February.
The case is a ground breaking as it’s one of the first times that recombinant human growth hormone has been detected using new technology.
The 30-year-old Sinkewitz already served a racing ban after testing positive for testosterone in 2007. If a second round of testing confirms the preliminary adverse analytical finding (jargon for positive), the German could be banned for life in what would be a second doping case.
Sinkewitz was on his team’s roster to start Saturday’s Milan-San Remo. No word from the team yet on his substitute.
Here is the UCI statement released Friday:
Earlier today, the UCI advised German rider Patrik Sinkewitz that he is provisionally suspended. The decision to provisionally suspend Mr Sinkewitz was made in response to a report from the WADA accredited laboratory in Lausanne indicating an Adverse Analytical Finding of Recombinant Human Growth Hormone in a blood sample collected from him at an in-competition test carried out by Antidoping Switzerland, authorized by the UCI, at the GP di Lugano on 27 February 2011.
This is the first suspension delivered in cycling on the basis of a test for the detection of the growth hormone and one of the first cases in all sports combined. This adverse analytical finding is therefore a new and important step in cycling’s fight against doping.
The provisional suspension remains in force until a hearing panel convened by the German Cycling Federation determines whether Mr Sinkewitz has committed an anti-doping rule violation under Article 21 of the UCI Anti-Doping Rules.
Mr Sinkewitz has the right to request and attend the analyses of his B sample.
Under the World Anti-Doping Code and the UCI Anti-Doping Rules, the UCI is unable to provide any additional information at this time.